These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1960753)

  • 1. Modeling interpatient pharmacodynamic variability of etoposide.
    Mick R; Ratain MJ
    J Natl Cancer Inst; 1991 Nov; 83(21):1560-4. PubMed ID: 1960753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
    Ratain MJ; Schilsky RL; Choi KE; Guarnieri C; Grimmer D; Vogelzang NJ; Senekjian E; Liebner MA
    Clin Pharmacol Ther; 1989 Mar; 45(3):226-33. PubMed ID: 2920497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic modeling of prolonged administration of etoposide.
    Minami H; Ratain MJ; Ando Y; Shimokata K
    Cancer Chemother Pharmacol; 1996; 39(1-2):61-6. PubMed ID: 8995500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
    Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
    Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
    Mick R; Vokes EE; Lestingi TM; Gray-Stern W; Fleming GF; Schilsky RL; Ratain MJ
    Clin Pharmacol Ther; 1996 Mar; 59(3):349-59. PubMed ID: 8653998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
    Ratain MJ; Mick R; Schilsky RL; Vogelzang NJ; Berezin F
    J Clin Oncol; 1991 Aug; 9(8):1480-6. PubMed ID: 2072147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New perspectives on the toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):78-83. PubMed ID: 1492230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and long-term toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S64-8. PubMed ID: 8070030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting etoposide toxicity: relationship to organ function and protein binding.
    Joel SP; Shah R; Clark PI; Slevin ML
    J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
    Miller AA; Tolley EA; Niell HB
    Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.
    Miller AA; Tolley EA; Niell HB; Griffin JP; Mauer AM
    J Clin Oncol; 1993 Jun; 11(6):1179-88. PubMed ID: 8388920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect-response model for the time course of leukopenia with anticancer drugs.
    Minami H; Sasaki Y; Saijo N; Ohtsu T; Fujii H; Igarashi T; Itoh K
    Clin Pharmacol Ther; 1998 Nov; 64(5):511-21. PubMed ID: 9834043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
    Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
    Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
    Goh BC; Fleming GF; Janisch L; Vogelzang NJ; Stadler WM; Ratain MJ
    Cancer Chemother Pharmacol; 2000; 45(6):489-94. PubMed ID: 10854137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days.
    van der Gaast A; Vlastuin M; Kok TC; Splinter TA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):8-12. PubMed ID: 1488657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.
    Minami H; Ando Y; Sakai S; Shimokata K
    J Clin Oncol; 1995 Jan; 13(1):191-9. PubMed ID: 7799020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
    Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
    Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.